Advertisement

Topics

N-of-One® Dramatically Speeds High-Accuracy Interpretation of the Illumina TrueSight Tumor170 Cancer Panel

08:30 EST 21 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
N-of-One, Inc., founded in 2008 as a leader in interpretation of molecular tests in oncology, announced today the launch of RapidInsights for Illumina’s TruSight Tumor 170 (TST170). RapidInsights is a fully automated interpret...

Other Sources for this Article

N-of-One, Inc.
Emily Cavanaugh, 617-761-6748
emily.cavanagh@fkhealth.com
or
Illumina
Jen Carroll, 858-882-6822
PR@illumina.com

NEXT ARTICLE

More From BioPortfolio on "N-of-One® Dramatically Speeds High-Accuracy Interpretation of the Illumina TrueSight Tumor170 Cancer Panel"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...